NLRP3 and neoplasm: Therapeutical strategies targeting the NLRP3 inflammasome in OC involve the use of Oridonin, which, through the suppression of the mTOR pathway, arrests OC spread [185], and Tranilast, which enhances the sensitivity of tumor cells to Cisplatin [186].